Positron emission tomography in patients with aggressive fibromatosis/desmoid tumours undergoing therapy with imatinib

We used 18F-FDG PET to evaluate the FDG uptake in patients with aggressive fibromatosis (AF, also known as desmoid tumours) undergoing therapy with imatinib (imatinib mesylate, Glivec).

Saved in:

Bibliographic Details
Main Authors:	Kasper, Bernd (Author) , Dimitrakopoulou-Strauss, Antonia (Author) , Strauss, Ludwig G. (Author) , Hohenberger, Peter (Author)
Format:	Article (Journal)
Language:	English
Published:	19 June 2010
In:	European journal of nuclear medicine and molecular imaging Year: 2010, Volume: 37, Issue: 10, Pages: 1876-1882
ISSN:	1619-7089
DOI:	10.1007/s00259-010-1498-x
Online Access:	Resolving-System, lizenzpflichtig, Volltext: https://doi.org/10.1007/s00259-010-1498-x Verlag, lizenzpflichtig, Volltext: https://link.springer.com/article/10.1007/s00259-010-1498-x
Author Notes:	Bernd Kasper, Antonia Dimitrakopoulou-Strauss, Ludwig G. Strauss, Peter Hohenberger

Description
Summary:	We used 18F-FDG PET to evaluate the FDG uptake in patients with aggressive fibromatosis (AF, also known as desmoid tumours) undergoing therapy with imatinib (imatinib mesylate, Glivec).
Item Description:	Gesehen am 07.03.2023
Physical Description:	Online Resource
ISSN:	1619-7089
DOI:	10.1007/s00259-010-1498-x